Wells, JE, Browne, MAO, Scott, KM, McGee, MA, Baxter, J, Kokaua, J. Prevalence, interference with life and severity of 12 month DSM-IV disorders in Te Rau Hinengaro: The New Zealand Mental Health Survey. Aust NZ J Psychiatry
2006; 40: 845–54.
Hall, W, Teesson, M, Lynskey, M, Degenhardt, L. The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-Being. Addiction.
1999; 94: 1541–50.
Oakley Browne, MA, Wells, JE, Scott, KM, Mcgee, MA. Lifetime prevalence and projected lifetime risk of DSM-IV disorders in Te Rau Hinengaro: the New Zealand Mental Health Survey. Aust NZ J Psychiatry
2006; 40: 865–74.
Kessler, RC, Berglund, P, Demler, O, Jin, R, Merikangas, KR, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry
2005; 62: 593.
Wells, JE, Bushnell, JA, Hornblow, AR, Joyce, PR, Oakley-Browne, MA. Christchurch Psychiatric Epidemiology Study, Part I: Methodology and lifetime prevalence for specific psychiatric disorders. Aust NZ J Psychiatry
1989; 23: 315–26.
Wells, JE, Horwood, LJ, Fergusson, DM. Stability and instability in alcohol diagnosis from ages 18 to 21 and ages 21 to 25 years. Drug Alcohol Dep
2006; 81: 157–65.
Rehm, J, Mathers, C, Popova, S, Thavorncharoensap, M, Teerawattananon, Y, Patra, J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet
2009; 373: 2223–33.
Lloyd, B, Barratt, MJ, Ferris, J, Best, D, Lubman, DI. Factors influencing mortality among alcohol and drug treatment clients in Victoria, Australia: the role of demographic and substance use characteristics. Aust NZ J Psychiatry
2013; 47: 859–67.
Sellman, D. The 10 most important things known about addiction. Addiction
2010; 105: 6–13.
Sheedy, CK, Whitter, M. Guiding Principles and Elements Of Recovery-Oriented Systems of Care: What do We Know from the Research?
. Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 2009.
Marlatt, GA, Blume, AW, Parks, GA. Integrating harm reduction therapy and traditional substance abuse treatment. J Psychoactive Drugs
2001; 33: 13–21.
Ilgen, M, McKellar, J, Tiet, Q. Abstinence self-efficacy and abstinence 1 year after substance use disorder treatment. J Consult Clin Psychol
2005; 73: 1175.
Hunt, WA, Barnett, LW, Branch, LG. Relapse rates in addiction programs. J Clin Psychol
1971; 27: 455–6.
Keen, J, Oliver, P, Rowse, G, Mathers, N. Residential rehabilitation for drug users: a review of 13 months' intake to a therapeutic community. Fam Pract
2001; 18: 545–8.
Gossop, M. The treatment mapping survey; a descriptive study of drug and alcohol treatment responses in 23 countries. Drug Alcohol Depend
1995; 39: 7–14.
Gossop, M, Marsden, J, Stewart, D, Rolfe, A. Treatment retention and 1 year outcomes for residential programmes in England. Drug Alcohol Depend
1999; 57: 89–98.
Siqueland, L, Crits-Christoph, P, Frank, A, Daley, D, Weiss, R, Chittams, J, et al. Predictors of dropout from psychosocial treatment of cocaine dependence. Drug Alcohol Depend
1998; 52: 1–13.
Gossop, M, Marsden, J, Stewart, D, Lehmann, P, Edwards, C, Wilson, A, et al. Substance use, health and social problems of service users at 54 drug treatment agencies. Intake data from the National Treatment Outcome Research Study. Br J Psychiatry
1998; 173: 166–71.
Siddall, JW, Conway, GL. Interactional variables associated with retention and success in residential drug treatment. Subst Use Misuse
1988; 23: 1241–54.
Meier, PS, Barrowclough, C, Donmall, MC. The role of the therapeutic alliance in the treatment of substance misuse: a critical review of the literature. Addiction
2005; 100: 304–16.
Meier, PS, Meier, PS, Best, D. Programme factors that influence completion of residential treatment. Drug Alcohol Rev
2006; 25: 349–55.
Darke, S, Campbell, G, Popple, G. Retention, early dropout and treatment completion among therapeutic community admissions. Drug Alcohol Rev
2012; 31: 64–71.
Mulder, R, Frampton, C, Peka, H, Hampton, G, Marsters, T. Predictors of 3-month retention in a drug treatment therapeutic community. Drug Alcohol Rev
2009; 28: 366–71.
DeLeon, G, Melnick, G, Thomas, G, Kressel, D, Wexler, HK. Motivation for treatment in a prison based therapeutic community. Am J Drug Alcohol Abuse
2000; 26: 33–46.
Brunette, M, Mueser, K, Drake, R. A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev
2004; 23: 471–81.
Vitellone, N. Habitus and social suffering: culture, addiction and the syringe. Sociol Rev
2004; 52 (s2): 129–47.
Taylor, K, Thompson, S, Davis, R. Delivering culturally appropriate residential rehabilitation for urban Indigenous Australians: a review of the challenges and opportunities. Aust NZ J Publ Health
2010; 34(s1): S36–40.
Vederhus, JK, Kristensen, Ø, Laudet, A, Clausen, T. Attitudes towards 12-step groups and referral practices in a 12-step naive treatment culture; a survey of addiction professionals in Norway. BMC Health Serv Res
2009; 9: 147.
Huriwai, T, Sellman, JD, Sullivan, P, Potiki, TL. Optimal treatment for Maori with alcohol and drug-use-related problems: an investigation of cultural factors in treatment. Subst Use Misuse
2000; 35: 281–300.
Whiteford, H, Harris, M, Diminic, S. Mental health service system improvement: translating evidence into policy. Aust NZ J Psychiatry
2013; 47: 703–6.
Prussing, E. Sobriety and its cultural politics: an ethnographer's perspective on ‘culturally appropriate’ addiction services in Native North
2008; 36: 354–75.
Meier, P. A National Survey of Retention in Residential Rehabilitation Services.
National Treatment Agency for Substance Misuse, 2005.
Marsden, J, Farrell, M, Bradbury, C, Dale-Perera, A, Eastwood, B, Roxburgh, M, et al. Development of the treatment outcomes profile. Addiction
2008; 103: 1450–60.
Sheerin, I, Green, T, Sellman, D, Adamson, S, Deering, D. Reduction in crime by drug users on a methadone maintenance therapy programme in New Zealand. NZ Med J
2004; 117: 1–10.
Johns, K, Baker, A, Webster, RA, Lewin, TJ. Factors associated with retention in a long-term residential rehabilitation programme for women with substance use problems. Ment Health Subst Use Dual Diagn
2009; 2: 40–51.
Bouchery, EE, Harwood, HJ, Sacks, JJ, Simon, CJ, Brewer, RD. Economic costs of excessive alcohol consumption in the US, 2006. Am J Prevent Med
2011; 41: 516–24.
Zhang, Z, Friedmann, PD, Gerstein, DR. Does retention matter? Treatment duration and improvement in drug use. Addiction
2003; 98: 673–84.
Simpson, DD, Joe, GW, Brown, BS. Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav
1997; 11: 294.
Huriwai, T, Sellman, J, Sullivan, P, Potiki, T. A clinical sample of Maori being treated for alcohol and drug problems in New Zealand. NZ Med J
1998; 111: 145.
McNaughton, CC. Transitions through homelessness, substance use, and the effect of material marginalization and psychological trauma. Drugs Educ Prev Policy
2008; 15: 177–88.
Simpson, DD, Joe, GW, Broome, KM, Hiller, ML, Knight, K, Rowan-Szal, GA. Program diversity and treatment retention rates in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav
1997; 11: 279.